GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alligator Bioscience AB (FRA:7AL0) » Definitions » Total Long-Term Liabilities

Alligator Bioscience AB (FRA:7AL0) Total Long-Term Liabilities : €2.96 Mil (As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is Alligator Bioscience AB Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Alligator Bioscience AB's Total Long-Term Liabilities for the quarter that ended in Mar. 2025 was €2.96 Mil.

Alligator Bioscience AB Total Long-Term Liabilities Historical Data

The historical data trend for Alligator Bioscience AB's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alligator Bioscience AB Total Long-Term Liabilities Chart

Alligator Bioscience AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.59 0.34 1.46 0.67 2.91

Alligator Bioscience AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Total Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.48 0.29 0.12 2.91 2.96

Alligator Bioscience AB Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Alligator Bioscience AB Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Alligator Bioscience AB's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Alligator Bioscience AB Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alligator Bioscience AB (FRA:7AL0) » Definitions » Total Long-Term Liabilities
Comparable Companies
OSTO:ACOU OSTO:EXPRS2 OSTO:ONCOZ OSTO:BIOVIC B OSTO:NXTCL XSAT:NIDHOG XSAT:CHOSA OSTO:SPAGO OSTO:MODTX OSTO:2CUREX VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
ATORX:Sweden 0RK9:UK
Address
Medicon Village, Scheeletorget 1, Lund, SWE, 223 81
Website
https://www.alligatorbioscience.se
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. Its drug candidate mitazalimab, is currently in preparation for Phase 3 development, and has previously presented unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1.

Alligator Bioscience AB Headlines

No Headlines